Detection of chromosomal translocations : In leukemia-lymphoma cells by polymerase chain reaction

Leukemia and Lymphoma

Volumn 19, Issue 5-6, 1995, Pages 359-380

  Drexler, Hans G ^a   Borkhardt, Arndt ^b   Janssen, Johannes W G ^c  

^a LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Chromosomal translocations; Leukemia lymphoma

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CELL STRUCTURE; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIAGNOSTIC ACCURACY; FOLLICULAR LYMPHOMA; GENE SEQUENCE; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA; LEUKEMIA REMISSION; LYMPHOMA; METHODOLOGY; MOLECULAR CLONING; PATHOLOGY; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; RISK; TREATMENT FAILURE;

CHROMOSOME ABERRATIONS; DNA, NEOPLASM; HUMAN; LEUKEMIA; LYMPHOMA; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; ONCOGENES; POLYMERASE CHAIN REACTION; SUPPORT, NON-U.S. GOV'T; TRANSCRIPTION FACTORS; TRANSLOCATION (GENETICS); TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELLS;

EID: 0028892574     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199509112194     Document Type: Article

References (278)

1. Structural anti functional chimerism results from chromosomal translocation in lymphoid tumors
2. The role of oncogenes in hematologic malignancies
3. The molecular basis of leukemia
4. Molecular themes in oncogenesis
5. Cooperation between oncogenes
6. Tumor suppressor genes
7. Oncogenic conversion of transcription factors by chromosomal translocations
8. Translocations, master genes, and differences between the origins of acute and chronic leukemias
9. Chromosome aberrations and cancer
10. Chromosomal translocations in leukaemia
11. Chimaeric oncoproteins resulting from chromosomal translocations in acute lymphoblastic leukaemia
12. Bcl-2 initiates a new category of onco-genes: Regulators of cell death
13. LIM domain proteins in leukaemia and development
14. The human T cell receptor genes are targets for chromosomal abnormalities in T cell tumors
15. Activation of cellular oncogenes in hematopoietic cells by chromosome translocation
16. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes
17. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32)and t(3;22)(q27;q11) in B-cell lymphomas
18. LAZ3, a novel zinc-finger encoded gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas
19. Molecular cloning of the breakpoint for 3q27 translocation in B-cell lymphomas and leukemias
20. Alterations of a zinc-finger encoding gene, BCL6, in diffuse large-cell lymphoma
21. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma
22. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene
23. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells
24. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytomacells
25. Molecular basis of human B cell neoplasia
26. Activation of MYC in a masked t(8; 17) translocation results in an aggressive B-cell leukemia
27. Identification of a human transcription unit affected by the variant chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma
28. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homoglous to NF-ΚB p50
29. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation
30. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation
31. A novel cyclin encoded by a bcl I-linked candidate oncogene
32. Characterization of a candidate bcl-1 gene
33. PRAD1, a candidate BCL1 oncogene: Mapping and expression in centrocytic lymphoma
34. bcl-1, t(11;14), and mantle cell-derived lymphomas
35. Molecular cloning of the chromosomal breakpoint of a B-cell lymphoma with the t(11;14)(q23;q32) translocation
36. Cloning, expression and localization of an RNA helicase gene from a human lymphoid cell line with chromosomal breakpoint 11q23.3
37. Cloning of the chromosome breakpoint of neoplas-tic B cells with the t(14;18) chromosome translocation
38. H on chromosome 14 and near a transcriptional unit on 18
39. Nucleotide sequence of a t(14; 18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18
40. Bcl-2/Bax: A rheostat that regulates an anti-oxidant pathway and cell death
41. FVT-I, a novel human transcription unit affected by variant translocation t(2;18)(p11;q21) of follicular lymphoma
42. Cloning of the chromosome translocation breakpoint junction of the t(14; 19) in chronic lymphocytic leukemia
43. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control
44. Chromosomal translocations joining LCK and TCRB loci in human T cell leukemia
45. Chromosomal translocation in a human leukemic stem-cell line disriupts the T-cell antigen receptor δ-chain diversity region and results, in a previously unreported fusion transcript
46. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia
47. Involvement of the TCL5 gene on chromosome 1 in T-cell leukemia and melanoma
48. c-tal, a helix-loop-helix protein, is juxtaposed to the T-cell receptor-β chain gene by a reciprocal chromosomal translocation: t(1;7)(p32;q35)
49. Disruption of the SCL gene by a t(1;3) translocation in a patient with T cell acute lymphoblastic leukemia
50. TAL1, TAL2 and LYL1: A family of basic helix-loop-helix proteins implicated in T cell mute leukaemia
51. TAL2, a helix-loop-helix gene activated by the (7;9(q34;q32) translocation in human T-cell leukemia
52. Analysis of DNA surrounding the breakpoints of chromosomal translocations involving the β T cell receptor gene in human lymphoblastic neoplasms
53. Consistent breakage between consensus recombinase heptamers of chromosome 9 DNA in a recurrent chromosomal translocation of human T cell leukemia
54. TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms
55. Chromosomal translocation involving the β T cell receptor gene in acute leukemia
56. lyl-l, a novel gene altered by chromosomal translocation in T cell leukemia, codes for a protein with a helix-loop-helix DNA binding motif
57. Molecular cloning of the breakpoint junction of a human chromosomal 8; 14 translocation involving the T-cell receptor α-chain gene and sequences on the 3′ side of
58. Chromosomal translocation in T-cell leukemia line HUT 78 results in a MYC fusion transcript
59. The t(10;14)(q24;q11) of T-cell acute lymphoblastic leukemia juxtaposes the y T-cell receptor with TCL3, a conserved and activated locus at 10q24
60. Deregulation of a homeobox gene, hox11, by the t(10; 14) in T cell leukemia
61. HOX11, a home-obox-containing T-cell oncogene on human chromosome 10q24
62. The HOX11 gene encodes a DNA-binding nuclear transcription factor belonging to adistinct family of homeobox genes
63. The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg-l, a gene encoding a potential zinc finger protein
64. The rhombotin family of cysteine-rich LIM-domain oncogenes: Distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13
65. TTG-2, a new gene encoding a c:ysteine-rich protein with, the: LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11)
66. Fusion of an immunoglobulin variable gene and a T cell receptor constant gene in the chromosome 14 inversion associated with T cell tumors
67. Gene for α-chain of human T-cell receptor: Location on chromosome 14 region involved in T-cell neoplasms
68. A chromosome 14 inversion in a T-cell lymphoma is caused by site-specific recombination between irnmunoglobulin and T-cell receptor loci
69. Juxtaposition of the T-cell receptor α-chain locus (14q11) and a region (14q32) of potential importance in leukemogenesis by a 14;1.4 translocation in a patient with T-cell chronic lymphocytic leukemia and ataxia-telangiectasia
70. Molecular analysis of a t(7; 14)(q35;q32) chromosome translocation in a T cell leukemia of a patient with ataxia telangiectasia
71. MTCP-1: A novel gene on the human chromosome Xq28 translocated to the T cell receptor α/γ locus in mature T cell proliferations
72. A gene on chromosome Xq28 associalted wi th T-cell pro-lymphocytic leukemia iin two patients with ataxia telangiectasia
73. Cloning of ALL-l, the locus involved in leukemias with the t(4;11)(q21:q23), t(9;11)(p22:q23), and t(11;19)(q23:p13) chromosome translocations
74. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocalions associated with human leukemias
75. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias
76. Cloning of cDNAs of the MLL gene that detect DNA rearrangements and altered RNA transcripts in human leukemic cells with 11q23 transllocations
77. Structure and expression of the human trithorax-like gene 1 involved in acute leukemias
78. Rearrangements involving chromosome band 11q23 in acute leukaemia
79. A novel gene, AF-1p, fused to HRX in t(1; 11)(p32;q23), is not related to AF-4, AF-9 nor ENL
80. The gene for enhancer binding proteins E12/E47 lies at the (1;19) breakpoint in acute leukemias
81. A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL
82. Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor
83. Nucleophosmin (NPM) gene rearrangements in Ki-1-positive lymphomas
84. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
85. Evi-1 expression in leukemic patients with rearrangements of the 3Q25-Q28 chromosomal region
86. Activation of EVII gene expression in human acute myelogenous leukemias by translocations spanning 300–400 kilobases on chromosome band 3q26
87. DNA rearrangements proximal to the EVII locus associated with the 3q21q26 syndrome
88. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene
89. Involvement of the AML1 gene in the (3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis
90. The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1
91. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations
92. The AML1 and ETO genes in acute myeloid leukemia with a t(8;21)
93. Generation of the AMLI-EVI-I fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia
94. The t(4; 11) chromosome translocation of human acute leukemia fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene
95. A serine/proline-rich protein is fused to HRX in t(4;11) acute leukemias
96. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product
97. The MLL (11q23) and AF-4 (4q21) genes disrupted in t(4; 11) acute leukemia: Molecular and clinical studies
98. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
99. The t(5; 17) translocation in acute promyelocytic leukemia generates a nucleophosmin-RARa fusion transcript
100. The (6;9) chromosome translocation, associated with a specific subtype of acute nonlymphocytic leukemia, leads to aberrant transcription of a target gene on 9q34
101. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek, can, and the expression of a chimeric, leukemia-specific dek-can mRNA
102. can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: Characterization of the set gene
103. The translocation (6;9)(p23;q34) shows consistent rearrangements of two genes and defines a myeloproliferative disorder with specific clinical features
104. Dek-Can rearrangement in translocation (6;9)(p23;q34)
105. Cloning of the ALL-1 fusion partner, the AF-6 gene, involved in acute myeloid leukemias with t(6;1 1) chromosome translocation
106. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1
107. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript
108. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AMLf1ETO, with similarity to Drosophila segmentation gene
109. Molecular basis of the t(8;21) translocation in acute myeloid leukaemia
110. Translocation breakpoints are clustered on both chromosome 8 and chromosome 21 in the t(8;21) of acute myeloid leukemia
111. Genes on chromosomes 4, 9 and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs
112. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelo-cytic leukaemia
113. Localization of the c-abl oncogene adjacent to a translocation breakpoint in chronic myelocytic leukaemia
114. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
115. Fused transcript of abl, bcr genes in chronic myelogenous leukaemia
116. The chronic myelogenous leukemia-specific p210 protein is the product of the bcr/abl hybridgene
117. Unique fusion of bcr and c-abl genes in Philadelphia chromosome-positive acute lym-phoblastic leukemia
118. The molecular genetics of Philadelphia chromosome-positive leukemia
119. Molecular cloning of the gene (AF10) involved in the t(10;11)(p12;q23) translocation in acute leukaemia reveals a new class of conserved zinc fingdleucine zipper proteins
120. Fusion between a novel Krüppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia
121. PLZF-RARα fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors
122. Acute promyelocytic leukaemia and the t(15:17) translocation
123. Leucine-zipper dimerization motif encoded by the AF17 gene fused to ALL-1 (MLL) in acute leukemia
124. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias
125. Cloning of a novel gene, ELL, that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia
126. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus
127. The PML-RARα fusion mRNA generated by the t(15; 17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
128. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17
129. Cloning and characterization of the t(15;17) translocation breakpoint region in acute promyelocytic leulkemia
130. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor α locus
131. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML
132. Acute promyelocytic leukemia
133. Acute promyelocytic leukemia: From genetics to treatment
134. The t(15; 17) translocation in acute promyelocytic leukemia
135. Fusion between transcription factor CBFβ/PEBP2β and a myosin heavy chain in acute myeloid leukemia
136. Identification of yeast artificial chromosomes containing the inversion 16 p-arm breakpoint associated with acute myelomono-cytic leukemia
137. Cloning the breakpoint cluster region of the inv(16) in acute myelomonocytic leukemia M4 Eo
138. Fusion of the dominant negative trnnscription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma
139. An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation
140. HLF, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia
141. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia
142. Acute leukemias of different lineages have similar MLL gene fusions encoding related chimeric proteins resulting from chromosomal translocation
143. Cloning and characterization of the t(X; 11) breakpoint from a leukemic cell line identify a new member of the forkhead gene family
144. Eukaryotic transcription factors
145. Transcriptional regulation in mammalian cells by sequence-specific DNA binding proteins
146. Transcription factors, translocations, and leukemia
147. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction
148. Monitoring minimal residual disease in acute leukemia: Expectations, possibilities and initial clinical results
149. Fluorescence in situ hybridization in leukemias: “The FISH are spawning”
150. Clinical value of PCR in diagnosis and follow-up of leukaemia and lymphoma: Report of the Third Workshop of the Molecular Biology/BMT Study Group
151. The use of the polymerase chain reaction for the detection of minimal residual malignant disease
152. Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: An updated meeting report and review
153. Detection of minimal residual leukemia by the polymerase chain reaction: Potential implications for therapy
154. Polymerase chain reaction (PCR) approach for the evaluation of minimal residual disease in acute leukemia
155. Rearrangements of the tal-l locus as clonal markers for T-cell acute lymphoblastic leukemia
156. Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor αβ lineage
157. Frequency and DNA sequence of tal-I rearrangement in children with T-cell acute lymphoblastic leukemia
158. tal-I deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual desease
159. SIL-TAL-I deletion in T-cell acute lymphoblastic leukemia
160. Detection of minimal residual disease in leukemic patients with the t(10;14)(q24;q11) chromosomal translocation
161. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas
162. Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas
163. A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-I gene
164. Detection of minimal residual cells canying the t(14;18) by DNA sequence amplification
165. Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease
166. Detection of occult follicular lymphoma by specific DNA amplification
167. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas
168. Detection of 14; 18 chromosomal translocation in paraffin-embedded lymphoma tissue
169. The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma
170. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment
171. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma
172. Detection of residual disease in translocation (14;18) positive non-Hodgkin's lymphoma, using the polymerase chain reaction: A comparison with conventional staging methods
173. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
174. Sensitive and reproducible detection of occult disease in patients with follicular lymphoma by PCR amplification of t(14;18) both pre- and post-treatment
175. Persistence of circulating t(14; 18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma
176. Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular Non-Hodgkin's lymphoma
177. Analysis of the expression of the hybrid gene bcl-2/IgH in follicular lymphoma
178. Clinical significance of 1.(14;18)-positive cells in the circulation of patients with stage III or IV follicular Non-Hodgkin's lymphoma during first remission
179. The t(1;19)(q23;p13) results in consistent fusion of E2A, PEXI coding sequences in acute lymphoblastic leukemias
180. Multiprimer-PCR for screening of genetic abnormalities in acute lymphoblastic leukaemia
181. Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: A comparison between cyto-genetic and polymerase chain reaction analyses
182. Different molecular consequences of the 1; 19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia
183. Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation
184. Heterogeneity in MLL/AF-4 fusion messenger RNA detected by the polymerase chain reaction in t(4;11) acute leukemia
185. The der(II)-encoded MLL/AF-4 fusion transcript is consistently detected in t(4;11)(q21, q23)-containing acute lymphoblastic leukemia
186. A reverse transcriptase-polymerase chain reaction detects heterogeneous chimeric mRNAs in leukemias with 11q23 abnormalities
187. Detection of HRX-FEL fusion transcripts in pre-pre-B-ALL with and without cytogenetic demonstration of t(4;11)
188. Molecular analysis of MLL-1/AF4 recombination in infant acute lymphoblastic leukemia
189. Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DNA-fragment analysis
190. Pre-pre-B acute lymphoblastic leukemia: High frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission
191. An AMLI/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21)(q22;q22) translocation
192. Junctions of the AMLI/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase: chain reaction
193. Detection of DNA rearrangements in the AML1, ETO loci and of, an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia
194. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission
195. Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia
196. Detection of the AML1/ETO fusion transcript in the t(8;21) masked translocation in acute myelogenous leukemia
197. Detection of AMLI/ETO fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia
198. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation
199. AML-1 gene rearrangement and AML-1-ETO gene expression as molecular markers of acute myeloblastic leukemia with t(8;21)
200. Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation
201. Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction
202. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified
203. Detection of the molecular abnormality in chronic myeloid leukemia by use of the polymerase chain reaction
204. bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia
205. Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia
206. Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia
207. Polymerase chain reaction for detection of residual leukaemia
208. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukaemia patients after bone-marrow transplantation
209. Detection by enzymatic amplification of bcr-abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia
210. Minimal residual leukaemia in chronic myeloid leukaemia patients after T-cell depleted bone-marrow transplantation
211. Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction
212. Detection of residual BCR/ABL transcripts in chronic myeloid leukaemia patients in complete remission using the polymerase chain reaction and nested primers
213. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction
214. Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia
215. Consistent involvement of the BCR gene by 9;22 breakpoints in pediatric acute leukemias
216. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia
217. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: Role of polymerase chain reaction in predicting relapse
218. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant inter-feron α-2b alone or in combination with interferon γ
219. Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia
220. Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction
221. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia
222. Complete cyto-genetic conversion in chronic myelocytic leukemia patients undergoing interferon α therapy: Follow-up with reverse polymerase chain reaction
223. Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia
224. Persistence of bcr-abl gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase
225. Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy
226. Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation
227. Minimal residual disease status in transplanted chronic myelogenous leukemia patients: Low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants
228. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction
229. Long persistence bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: A study of 64 patients
230. Minimal residual disease after bone marrow transplant for chronic myeloid leukemia detected by the polymerase chain reaction
231. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT)
232. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders
233. Persistence of dormant leukemic progenitors during interferon-induced remission in (chronic myelogenous leukemia—Analysis by polymerase chain reaction of individual colonies
234. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction
235. Mlolecular evaluation of response to all-trans-retinoic acid therapy in patients with acute promyelocytic leukemia
236. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia
237. The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: Targets for the detection of minimal residual disease by the polymerase chain reaction
238. Molecular monitoring of the myl/retinoic acid receptor-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction
239. A PML/retinoic acid receptor α fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia
240. Diagnosis of acute promyelocytic leukaemia by RT-PCR: Detection of PML-RARA, RARA-PML fusion transcripts
241. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor a clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia
242. Occurrence of distinct PML-RAR-α fusion gene isoforms in patients with acute promyelocytic leukemia detected by reverse transcriptase/polymerase chain reaction
243. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA
244. Reverse transcriptase-polymerase chain reaction for PML-RARα fusion transcripts in acute promyelocytic leukemia and its application to minimal residual leukemia detection
245. Acute promyelocytic leukemia: Clinical relevance of two major PML-RARα isoforms and deteclion of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse
246. Absence of reverse transcriptase-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission
247. Rapid achievement of PML-RARα polymerase chain reaction (PCR)-negativity by combined treatment with all-trans-retinoic acid and chemotherapy in acute promyelocylic leukemia: A pilot study
248. PML-RAR alpha PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2–3 months
249. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelsogenous leukemia
250. Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplificiation
251. E2A/HLF fusion cDNAs and the use of RT-PCR for the detection of minimal residual disease in t(17; 19)(q22;p13) acute lymphoblastic leukemia
252. Two types of genomic rearrangements create alternative E2A-HILF fusion proteins in t(17;19)-ALL
253. Leukemia cell lines: In vitro models for the study of chronic myeloid leukemia
254. Hematopoietic cell lines
255. Cell lines as in vitro mode15 of acute promyelocytic leukemia
256. Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia
257. Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction
258. Bcl-2/Jh rearrangements in benign lymphoid tissues with follicular hyperplasia
259. Detection of the t(14: 18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients
260. BCL2 translocation frequency rises with age in humans
261. Lymphoma associated translocation t(14; 18) in blood B-cells of normal individuals
262. Cellular characteristics of acute myeloblastic leukemia associated with t(8;21)(q22;q22)
263. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia
264. Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature
265. False-positive results with PCR to detect leukaemia-specific transcript
266. Clinical significance of bcr-abl gene rearrangement detected by the polymerase chain reaction after al-logeneic bone marrow transplantation in chronic myelogenous leukemia
267. Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation
268. Rearrangemant of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocation?
269. Expression pattern of the RARα-PML fusion gene in acute promyelocytic leukemia
270. Localization of the chromosome 15 breakpoints and expression of multiple PML-RARα transcripts in acute promyelocytic leukemia: A study of 28 Chinese patients
271. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia
272. Monitoring of treatment outcome in acute promyelocytic leukemia by RT-PCR
273. Clinical relevance of the PML/RAR-α gene rearrangement in acute promyelocytic leukaemia
274. Can the polymerase chain reaction be used to direct therapy?
275. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia
276. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation
277. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia